For the quarter ending 2026-03-31, COAG has $175,258K in assets. $13,708K in debts. $49,860K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 49,860 | |||
| Marketable securities | 113,671 | |||
| Prepaid expenses and other current assets | 5,900 | |||
| Total current assets | 169,431 | |||
| Property and equipment, net | 648 | |||
| Operating right-of-use assets | 939 | |||
| Other non-current assets | 4,240 | |||
| Total assets | 175,258 | |||
| Accounts payable | 5,682 | |||
| Accrued expenses and other current liabilities | 6,963 | |||
| Operating lease liabilities | 544 | |||
| Total current liabilities | 13,189 | |||
| Operating lease liabilities, net of current portion | 519 | |||
| Total liabilities | 13,708 | |||
| Preferred stock value-Series Seed Convertible Preference Shares And Convertible Preferred Stock | 5,236 | |||
| Preferred stock value-Series AConvertible Preference Shares And Convertible Preferred Stock | 63,536 | |||
| Preferred stock value-Series BConvertible Preference Shares And Convertible Preferred Stock | 134,975 | |||
| Preferred stock value-Series CConvertible Preference Shares And Convertible Preferred Stock | 156,421 | |||
| Stockholders' deficit-Ordinary Shares | 0 | |||
| Stockholders' deficit-Common Stock | 0 | |||
| Additional paid in capital | 6,366 | |||
| Accumulated other comprehensive (loss) income | -439 | |||
| Accumulated deficit | -204,545 | |||
| Total stockholders' deficit | -198,618 | |||
| Total liabilities, convertible preference shares, convertible preferred stock and stockholders' deficit | 175,258 | |||
Hemab Therapeutics Holdings, Inc. (COAG)
Hemab Therapeutics Holdings, Inc. (COAG)